aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Metagenomi, founded by pioneers in the CRISPR/CAS revolution, is dedicated to discovering and developing next-generation gene-editing systems aimed at treating genetic diseases. The company leverages metagenomics, the study of genomes recovered from uncultivated organisms in natural environments, to create potentially curative therapeutics. Metagenomi's innovative genome-editing toolbox aims to surpass current technological capabilities, offering precise and versatile therapeutic gene edits across the human genome.
Notable figures affiliated with Metagenomi include its founding scientists who have significantly contributed to advancements in CRISPR technology. The company has attracted substantial investment from leading biotech investors, enabling rapid progress in its research and development efforts. Metagenomi's breakthroughs in gene-editing tools have positioned it as a key player in the field of genetic medicine, with the potential to revolutionize treatments for a wide range of genetic disorders.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Gene Editing
Technology
Biotech, GenAI
Tags
Biotech
Model Types
Therapeutics
Revenue Type(s)
Enterprise, Small Business
Customer Type(s)
Global
When was Metagenomi founded?
Metagenomi was founded in 2016.
Where is Metagenomi's headquarters located?
Metagenomi's headquarters is located in Berkeley, CA, US.
When was Metagenomi's last funding round?
Metagenomi's most recent funding round was for $100M (USD) in January 2023.
How many employees does Metagenomi have?
Metagenomi has 191 employees as of Feb 4, 2024.
How much has Metagenomi raised to-date?
As of July 05, 2023, Metagenomi has raised a total of $457M (USD) since Jan 5, 2023.
Add Comparison
Total Raised to Date
$457M
USD
Last Update Jan 5, 2023
Last Deal Details
$100M
USD
Jan 5, 2023
Series B
Total Employees Over Time
191
As of Feb 2024
Metagenomi Address
1429 Edith Street
Berkeley,
California
94703
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts